Why the study?
Redox homeostasis appears crucial in the pathogenesis of heart and kidney disease in diabetes, and accumulating evidence suggests SGLT2 inhibitors offer cardio- and nephroprotective benefits through mechanisms including decreased oxidative stress.
Do SGLT2 inhibitors reduce oxidative stress in patients with heart failure and chronic kidney disease in diabetes mellitus?
Do SGLT2 inhibitors reduce oxidative stress in patients with heart failure and chronic kidney disease in diabetes mellitus?
SGLT2 inhibitors may exert cardio- and nephroprotective effects in diabetes through mechanisms involving the reduction of oxidative stress and improvement of redox homeostasis.
There is increasing interest in sodium-glucose cotransporter 2 inhibitors (SGLT2i) as not only a new oral glucose-lowering drug class but also one with cardio- and nephroprotective potential. Understanding the underlying mechanisms is therefore of great interest, and postulated benefits have included increased natriuresis, lower blood pressure, increased haematocrit, enhanced cardiac fatty acid utilization, reduced low-grade inflammation, and decreased oxidative stress. In particular, redox homeostasis seems to be crucial in the pathogenesis of heart and kidney disease in diabetes, and there is accumulating evidence that SGLT2i have beneficial effects in this perspective. In this review, we aimed to summarize the potential mechanisms of the influence of SGLT2i on oxidative stress parameters in animal and human studies, with a special focus on heart failure and chronic kidney disease in diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Nabrdalik-Leśniak et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: